Table 1.
Baseline co-variates of patients living with metastatic cancer, 1992–2019
| Deaths from all causes | |||||||
|---|---|---|---|---|---|---|---|
| Alive (N = 193,126) | Diagnosed Cancer (N = 688,529) | Non-cancer (N = 111,616) | Subsequent Cancer (N = 28,390) | Unknown (N = 9276) | Overall (N = 1,030,937) | ||
| Age group | |||||||
| 0–54 | 74,084 (38.4%) | 109,693 (15.9%) | 12,176 (10.9%) | 2662 (9.4%) | 2184 (23.5%) | 200,799 (19.5%) | |
| 55–64 | 47,589 (24.6%) | 146,840 (21.3%) | 15,959 (14.3%) | 5038 (17.7%) | 2032 (21.9%) | 217,458 (21.1%) | |
| 65–74 | 43,777 (22.7%) | 193,091 (28.0%) | 28,586 (25.6%) | 8793 (31.0%) | 2685 (28.9%) | 276,932 (26.9%) | |
| 75–84 | 21,965 (11.4%) | 171,609 (24.9%) | 35,794 (32.1%) | 8790 (31.0%) | 1844 (19.9%) | 240,002 (23.3%) | |
| 85+ | 4952 (2.6%) | 66,946 (9.7%) | 19,025 (17.0%) | 3102 (10.9%) | 522 (5.6%) | 94,547 (9.2%) | |
| Sex | |||||||
| Male | 98,051 (50.8%) | 358,696 (52.1%) | 63,664 (57.0%) | 15,404 (54.3%) | 5209 (56.2%) | 541,024 (52.5%) | |
| Female | 95,075 (49.2%) | 329,833 (47.9%) | 47,952 (43.0%) | 12,986 (45.7%) | 4067 (43.8%) | 489,913 (47.5%) | |
| Race | |||||||
| White | 150,372 (77.9%) | 546,256 (79.3%) | 89,663 (80.3%) | 23,473 (82.7%) | 5884 (63.4%) | 815,648 (79.1%) | |
| Black | 16,582 (8.6%) | 66,515 (9.7%) | 11,423 (10.2%) | 2558 (9.0%) | 732 (7.9%) | 97,810 (9.5%) | |
| Asian or Pacific Islander | 21,946 (11.4%) | 68,426 (9.9%) | 9303 (8.3%) | 2135 (7.5%) | 2488 (26.8%) | 104,298 (10.1%) | |
| American Indian/Alaska Native | 1803 (0.9%) | 6452 (0.9%) | 1040 (0.9%) | 215 (0.8%) | 57 (0.6%) | 9567 (0.9%) | |
| Year of diagnosis | |||||||
| 1992–1994 | 3059 (1.6%) | 60,892 (8.8%) | 9478 (8.5%) | 2635 (9.3%) | 817 (8.8%) | 76881 (7.5%) | |
| 1995–1999 | 8546 (4.4%) | 112,193 (16.3%) | 17,330 (15.5%) | 4659 (16.4%) | 1328 (14.3%) | 144,056 (14.0%) | |
| 2000–2004 | 17,163 (8.9%) | 129,438 (18.8%) | 21,575 (19.3%) | 5189 (18.3%) | 1725 (18.6%) | 175,090 (17.0%) | |
| 2005–2009 | 32,199 (16.7%) | 139,949 (20.3%) | 26,441 (23.7%) | 6361 (22.4%) | 1961 (21.1%) | 206,911 (20.1%) | |
| 2010–2014 | 52,676 (27.3%) | 142,835 (20.7%) | 23,602 (21.1%) | 6034 (21.3%) | 2009 (21.7%) | 227,156 (22.0%) | |
| 2015–2019 | 79,483 (41.2%) | 103,222 (15.0%) | 13,190 (11.8%) | 3512 (12.4%) | 1436 (15.5%) | 200,843 (19.5%) | |
| Primary cancer subsitea | |||||||
| Breast | 9376 (4.9%) | 27,778 (4.0%) | 3119 (2.8%) | 667 (2.3%) | 422 (4.5%) | 41,362 (4.0%) | |
| Colorectal | 7356 (3.6%) | 51,520 (7.4%) | 4756 (4.3%) | 1302 (4.5%) | 606 (6.5%) | 65,540 (6.4%) | |
| Corpus Uteri | 2813 (1.5%) | 8620 (1.3%) | 1148 (1.0%) | 301 (1.1%) | 124 (1.3%) | 13,006 (1.3%) | |
| Esophagus | 831 (0.4%) | 11,532 (1.7%) | 767 (0.7%) | 216 (0.8%) | 105 (1.1%) | 13,451 (1.3%) | |
| Kidney and Renal Pelvis | 2619 (1.4%) | 17,037 (2.5%) | 1456 (1.3%) | 471 (1.7%) | 206 (2.2%) | 21,789 (2.1%) | |
| Liver and Bile Duct | 852 (0.5%) | 11,779 (1.7%) | 1055 (1.0%) | 272 (0.9%) | 231 (2.5%) | 10,653 (1.0%) | |
| Lung and Bronchus | 14,833 (7.7%) | 225,999 (32.8%) | 17,827 (16.0%) | 5390 (19.0%) | 2196 (23.7%) | 266,245 (25.8%) | |
| Melanoma of the Skin | 1562 (0.8%) | 5099 (0.7%) | 562 (0.5%) | 255 (0.9%) | 51 (0.5%) | 7529 (0.7%) | |
| Ovary | 7835 (4.1%) | 30,436 (4.4%) | 2583 (2.3%) | 935 (3.3%) | 366 (3.9%) | 42,155 (4.1%) | |
| Pancreas | 2601 (1.3%) | 51,134 (7.4%) | 2374 (2.1%) | 920 (3.2%) | 503 (5.4%) | 57,532 (5.6%) | |
| Prostate | 8118 (4.2%) | 22,793 (3.3%) | 6272 (5.6%) | 1060 (3.7%) | 485 (5.2%) | 38,728 (3.8%) | |
| Stomach | 2031 (1.1%) | 23,284 (3.4%) | 1428 (1.3%) | 489 (1.7%) | 483 (5.2%) | 27,715 (2.7%) | |
| Urinary Bladder | 559 (0.3%) | 6251 (0.9%) | 665 (0.6%) | 300 (1.1%) | 48 (0.5%) | 7823 (0.8%) | |
Database “SEER Research Data, 12 Registries, Nov 2021 Sub (1992–2019) was used.
aRelative percent is in relation to all 80 primary cancer subtypes abstracted from SEER.